Induction of anti-VEGF therapy resistance by upregulated expression of microseminoprotein (MSMP)

Oncogene

Volumn 37, Issue 6, 2018, Pages 722-731

  Mitamura, T ^a,b   Pradeep, S ^a,c   McGuire, M ^a   Wu, S Y ^a   Ma, S ^a   Hatakeyama, H ^a   Lyons, Y A ^a   Hisamatsu, T ^a   Noh, K ^a,d   Villar Prados, A ^a   Chen, X ^a   Ivan, C ^a   Rodriguez Aguayo, C ^a   Hu, W ^a   Lopez Berestein, G ^a   Coleman, R L ^a   Sood, A K ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c MEDICAL COLLEGE OF WISCONSIN   (United States)

^d Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

B20 ANTIBODY; BEVACIZUMAB; CELL PROTEIN; MICROSEMINOPROTEIN; ONCOPROTEIN; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR CTCF; UNCLASSIFIED DRUG; VASCULOTROPIN ANTIBODY; ANGIOGENESIS INHIBITOR; PC3-SECRETED MICROPROTEIN, HUMAN; TUMOR MARKER; TUMOR PROTEIN; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC THERAPY; ARTICLE; CANCER CELL; CANCER RESISTANCE; CELL HYPOXIA; CHEMOSENSITIVITY; CONTROLLED STUDY; ENDOTHELIUM CELL; ENHANCER REGION; FEMALE; HISTONE ACETYLATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MAPK SIGNALING; MICROSEMINOPROTEIN BLOOD LEVEL; MOUSE; MSMP GENE; NONHUMAN; OVARY CANCER; PHARMACOGENETIC TESTING; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN SECRETION; TREATMENT RESPONSE; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; APOPTOSIS; CELL PROLIFERATION; DRUG RESISTANCE; DRUG SCREENING; FOLLOW UP; GENETICS; MALE; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); NUDE MOUSE; PATHOLOGY; PERITONEUM TUMOR; PROGNOSIS; TUMOR CELL CULTURE; UTERINE TUBE TUMOR;

ANGIOGENESIS INHIBITORS; ANIMALS; APOPTOSIS; BEVACIZUMAB; BIOMARKERS, TUMOR; CARCINOMA, OVARIAN EPITHELIAL; CELL HYPOXIA; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; FALLOPIAN TUBE NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MICE; MICE, NUDE; NEOPLASM PROTEINS; NEOVASCULARIZATION, PATHOLOGIC; PERITONEAL NEOPLASMS; PROGNOSIS; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85041519424     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2017.348     Document Type: Article

References (25)

1. Hillen F, Griffioen AW. Tumour vascularization: sprouting angiogenesis and beyond. Cancer Metastasis Rev 2007; 26: 489-502.
2. Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor-growth invivo. Nature 1993; 362: 841-844.
3. Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 2011; 365: 2473-2483.
4. Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 2011; 365: 2484-2496.
5. Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. J Clin Oncol 2014; 32: 1302-1308.
6. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342.
7. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A et al. Paclitaxelcarboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355: 2542-2550.
8. Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Ou SS et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 2008; 26: 5422-5428.
9. Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009; 27: 4733-4740.
10. Uhlen M, Oksvold P, Fagerberg L, Lundberg E, Jonasson K, Forsberg M et al. Towards a knowledge-based Human Protein Atlas. Nat Biotechnol 2010; 28: 1248-1250.
11. Pei X, Sun Q, Zhang Y, Wang P, Peng X, Guo C et al. PC3-secreted microprotein is a novel chemoattractant protein and functions as a high-affinity ligand for CC chemokine receptor 2. J Immunol 2014; 192: 1878-1886.
12. Valtonen-Andre C, Bjartell A, Hellsten R, Lilja H, Harkonen P, Lundwall A. A highly conserved protein secreted by the prostate cancer cell line PC-3 is expressed in benign and malignant prostate tissue. Biol Chem 2007; 388: 289-295.
13. Rosenbloom KR, Armstrong J, Barber GP, Casper J, Clawson H, Diekhans M et al. The UCSC Genome Browser database: 2015 update. Nucleic Acids Res 2015; 43: D670-D681.
14. Rosenbloom KR, Sloan CA, Malladi VS, Dreszer TR, Learned K, Kirkup VM et al. ENCODE data in the UCSC Genome Browser: year 5 update. Nucleic Acids Res 2013; 41: D56-D63.
15. Ghirlando R, Felsenfeld G. CTCF: making the right connections. Genes Dev 2016; 30: 881-891.
16. Kim MS, Kwon HJ, Lee YM, Baek JH, Jang JE, Lee SW et al. Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nat Med 2001; 7: 437-443.
17. Drappatz J, Lee EQ, Hammond S, Grimm SA, Norden AD, Beroukhim R et al. Phase I study of panobinostat in combination with bevacizumab for recurrent highgrade glioma. J Neurooncol 2012; 107: 133-138.
18. Lee EQ, Reardon DA, Schiff D, Drappatz J, Muzikansky A, Grimm SA et al. Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma. Neuro Oncol 2015; 17: 862-867.
19. Strickler JH, Starodub AN, Jia J, Meadows KL, Nixon AB, Dellinger A et al. Phase I study of bevacizumab, everolimus, and panobinostat (LBH-589) in advanced solid tumors. Cancer Chemother Pharmacol 2012; 70: 251-258.
20. Weth O, Paprotka C, Gunther K, Schulte A, Baierl M, Leers J et al. CTCF induces histone variant incorporation, erases the H3K27me3 histone mark and opens chromatin. Nucleic Acids Res 2014; 42: 11941-11951.
21. Bast RC Jr., Feeney M, Lazarus H, Nadler LM, Colvin RB, Knapp RC. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest 1981; 68: 1331-1337.
22. Buick RN, Pullano R, Trent JM. Comparative properties of five human ovarian adenocarcinoma cell lines. Cancer Res 1985; 45: 3668-3676.
23. Landen CN, Kim TJ, Lin YG, Merritt W, Kamat AA, Han L et al. Tumor-selective response to antibody-mediated targeting of alpha(v)beta(3) integrin in ovarian cancer. Neoplasia 2008; 10: 1259-1267.
24. Lau DH, Lewis AD, Ehsan MN, Sikic BI. Multifactorial mechanisms associated with broad cross-resistance of ovarian carcinoma cells selected by cyanomorpholino doxorubicin. Cancer Res 1991; 51: 5181-5187.
25. Yoneda J, Kuniyasu H, Crispens MA, Price JE, Bucana CD, Fidler IJ. Expression of angiogenesis-related genes and progression of human ovarian carcinomas in nude mice. J Natl Cancer Inst 1998; 90: 447-454.